# A Study of ASP1951 in Subjects With Advanced Solid Tumors

> **NCT03799003** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 119 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ASP1951
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03799003
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-14
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 119 (ACTUAL)
- **Why stopped:** Study was terminated for lack of efficacy.
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799003, "A Study of ASP1951 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03799003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*